Localized Resectable Genitourinary Sarcoma in Adult Korean Patients: Experiences at a Single Center.
10.3349/ymj.2011.52.5.761
- Author:
Sung Yong CHO
1
;
Kyung Chul MOON
;
Min Su CHEONG
;
Cheol KWAK
;
Hyeon Hoe KIM
;
Ja Hyeon KU
Author Information
1. Department of Urology, Seoul National University Hospital, Seoul, Korea. kuuro70@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Urogenital neoplasms;
sarcoma;
genitourinary tract;
survival;
prognosis
- MeSH:
Adult;
Aged;
Female;
Humans;
Immunohistochemistry;
Kaplan-Meier Estimate;
Male;
Middle Aged;
Neoplasm Grading;
Prognosis;
Republic of Korea;
Sarcoma/metabolism/pathology/*surgery;
Urogenital Neoplasms/metabolism/pathology/*surgery;
Young Adult
- From:Yonsei Medical Journal
2011;52(5):761-767
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the clinicopathological characteristics and prognosis of localized resectable genitourinary sarcomas in adults. MATERIALS AND METHODS: Between September, 1996 and November, 2008, 18 consecutive cases of adults (12 men and 6 women; median age 48.8 years) who were treated for primary genitourinary sarcomas were identified. The following variables were analyzed: patient age, gender, body mass index, American Society of Anesthesiologists (ASA) score, primary organ, tumor histology, size, necrosis, Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade, and surgical margin positivity. Recurrence-free survival and disease-specific survival were the study end-points. RESULTS: The most common presenting symptom was a palpable mass (six cases, 33.3%), the most common site was the kidney (six cases, 33.3%), and the most common histological subtype was leiomyosarcoma (eight patients, 44.4%). Complete resection with negative surgical margins was achieved in 13 patients (72.2%). The median follow-up period was 49.9 months (range 6.4 to 147.6). The recurrence-free survival rates at 1, 3, and 5 years were 81.6%, 66.5%, and 66.5%, respectively. Recurrence-free survival only associated significantly with ASA score (p=0.018). The disease-specific survival rate at 1, 3, and 5 years was 88.9%, 76.2%, and 67.7%, respectively. Disease-specific survival was associated significantly only with FNCLCC grade (p=0.042). CONCLUSION: Although genitourinary sarcomas in adults are a rare group of tumors with a poor prognosis, some patients may have a favorable prognosis. Our findings suggest that FNCLCC grade is the most important prognostic factor for these patients.
